[1]
|
Kabadi, U.M. (2008) Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Clinical Drug Investigation, 28, 697-701.
doi:10.2165/00044011-200828110-00003
|
[2]
|
American Diabetes Association (2011) Standards of medical care in diabetes-2011. Diabetes Care, 34, S11-S61.
|
[3]
|
Fritsche, A., Schweitzer, M.A. and Haring, H.U. (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine, 138, 952-959.
|
[4]
|
Schreiber, S.A., Ferlinz, K. and Haak, T. (2008) The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technology & Therapeutics, 10, 121-127. doi:10.1089/dia.2007.0265
|
[5]
|
Hammer, H. and Klinge, A. (2007) Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycemic control in daily practice. International Journal of Clinical Practice, 61, 2009-2018.
doi:10.1111/j.1742-1241.2007.01598.x
|
[6]
|
Standl, E., Maxeiner, S., Raptis, S., Karimi-Anderesi, Z. and Schweitzer, M.A. (2005) Good glycemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care, 28, 419-420.
doi:10.2337/diacare.28.2.419
|
[7]
|
Wang, Z.H., Hedrington, M.S., Joy, N.G., Briscoe, V.J., Richardson, M.A., Younk, L., Nicholson, W., Tate, D.B. and Davis, S.N. (2010) Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care, 33, 1555-1560.
doi:10.2337/dc09-2011
|
[8]
|
Swinnen, S.G. and De Vries, J.H. (2009) Higher dose requirements with insulin detemir in type 2 diabetes— Three cases and a review of the literature. Diabetes Research and Clinical Practice, 84, 24-26.
doi:10.1016/j.diabres.2009.02.009
|
[9]
|
Bott, S., Tusek, C., Jacobsen, L.V., et al. (2006) Insulin detemir under steady-state conditions: No accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabetic Medicine, 23, 522-528.
|
[10]
|
Pieber, T.R., Treichel, H.C., Hompesch, B., et al. (2007) Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabetic Medicine, 24, 635-642.
doi:10.1111/j.1464-5491.2007.02113.x
|
[11]
|
Dornhorst, A., Luddeke, H.J., Sreenan, S., et al. (2007) Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the predictive European cohort. International Journal of Clinical Practice, 61, 523-528.
doi:10.1111/j.1742-1241.2007.01316.x
|
[12]
|
Rosenstock, J., Davies, M., Home, P.D., Larsen, J., Koe- nen, C. and Schernthaner, G. (2008) A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-owering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51, 408-416.
doi:10.1007/s00125-007-0911-x
|
[13]
|
Hollander, P., Cooper, J., Bregnhoj, J. and Pedersen, C.B. (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clinical Therapeutics, 30, 1976-1987.
|
[14]
|
Raskin, P., Gylvin, T., Weng, W. and Chaykin, L. (2009) Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 25, 542-548.
doi:10.1002/dmrr.989
|
[15]
|
Johnson, C.K. and Shimshi, M. (2009) When a unit of insulin is not a unit: Detemir dosing and insulin cost in type 2 diabetes mellitus. Insulin, 4, 87-93.
doi:10.1016/S1557-0843(09)80017-1
|
[16]
|
Swinnen, S.G., Dain, M.P., Aronson, R., Davies, M., Gerstein, H.C., Pfeiffer, A.F., Snoek, F.J., Devries, J.H., Hoekstra, J.B. and Holleman, F.A. (2010) 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care, 33, 1176-1178.
doi:10.2337/dc09-2294
|
[17]
|
Dailey, G., Admane, K., Mercier, F. and Owens, D. (2010) Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: Comparing insulin glargine and insulin detemir. Diabetes Technology & Therapeutics, 12, 1019-1027. doi:10.1089/dia.2010.0063
|
[18]
|
Kato, T., Tokubuchi, I., Muraishi, K., Sato, S., Kato, T., Hara, K., Tanaka, K., Kaku, H., Tajiri, Y. and Yamada, K. (2010) Distinct pharmacodynamics of insulin glargine and insulin detemir: Crossover comparison in type 1 and type 2 diabetic patients on basal-bolus regimen. Diabetes Research and Clinical Practice, 90, 64-66.
doi:10.1016/j.diabres.2010.08.011
|
[19]
|
Lucidi, P., Porcellati, F., Rossetti, P., Candeloro, P., Cioli, P., Marzotti, S., Andreoli, A.M., Fede, R., Bolli, G.B. and Fanelli, C.G. (2011) Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: A randomized cross-over study. Diabetes Care, 34, 1312-1314.
doi:10.2337/dc10-1911
|
[20]
|
Malone, J.K., Kerr, L.F., Campaigne, B.N., Sachson, R.A. and Holcombe, J.H. (2004) Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargineplus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Therapeutics, 26, 2034-2044.
doi:10.1016/j.clinthera.2004.12.015
|
[21]
|
Kabadi, M.U. and Kabadi, U.M. (2003) Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. The Annals of Pharmacotherapy, 37, 1572-1576,
doi:10.1345/aph.1C492
|
[22]
|
Janka, H.U., Plewe, G., Riddle, M.C., Kliebe-Frisch, C., Schweitzer, M.A. and Yki-Jarvinen, H. (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 28, 254-259.
doi:10.2337/diacare.28.2.254
|
[23]
|
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R.A., Hu, P., Bode, B. and Garber, A. (2005) Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care, 28, 260-265.
|
[24]
|
Kabadi, U.M. (2006) Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Research & Clinical Practice, 72, 265-270.
doi:10.1016/j.diabres.2005.10.024
|
[25]
|
Ligthelm, R.J., Gylvin, T., DeLuzio, T. and Raskin, P.A. (2011) Comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: A randomized, open-label study. Endocrine Practice, 17, 41-50. doi:10.4158/EP10079.OR
|
[26]
|
Pscherer, S., Dietrich, E.S., Dippel, F.W. and Neilson, A.R. (2010) Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. International Journal of Clinical Pharmacology and Therapeutics, 48, 129-137.
|
[27]
|
Bierwirth, R.A., Kohlmann, T., Moock, J., Holle, R. and Landgraf, W. (2010) Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: Results of the LIVE-COM study. Medizinische Klinik (Munich), 105, 792-801. doi:10.1007/s00063-010-1136-1
|
[28]
|
Gilmer, T.P., O’Conner, P.J., Manning, W.G., et al. (1997) The cost to health plans of poor glycemic control. Diabetes Care, 20, 1847-1853.
doi:10.2337/diacare.20.12.1847
|
[29]
|
Gray, A., Raikoi, M., McGuire, A., et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes; economic analysis alongside randomized controlled trial (UKPDS 41). British Medical Journal, 320, 1373-1378. doi:10.1136/bmj.320.7246.1373
|
[30]
|
Testa, M.A. and Simonson, D.C. (1998) Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial. The Journal of the American Medical Association, 208, 1490-1496.
doi:10.1001/jama.280.17.1490
|
[31]
|
Adler, A.I., Stratton, I.M., Neil, H.A.W., et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. British Medical Journal, 321, 412-419.
doi:10.1136/bmj.321.7258.412
|
[32]
|
Skyler, J.S. (1996) Diabetic complications. The importance of glucose control. Endocrinology Metabolism Clinics of North America, 252, 243-254.
|
[33]
|
DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329, 977-986. doi:10.1056/NEJM199309303291401
|
[34]
|
Ohkubo, Y., Kishikawa, H., Araki, E., et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Research and Clinical Practice, 28, 103-117.
doi:10.1016/0168-8227(95)01064-K
|
[35]
|
United Kingdom Prospective Diabetes Study (UKPDS) (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 353, 837-853.
|